Quintiles eyes Chicago hospitals; CRO market may not be so sunny;

> All the R&D budget slashing in Big Pharma would seem to suggest a rise in demand for CROs, but Forbes warns that the expected growth may not be so robust. Article

> Quintiles is eyeing partnerships with two large Chicago hospitals, likely looking to conduct clinical trials there. Story

> PPD is expanding its cGMP cell-based assay laboratory, looking to meet a growing demand in the development of biosimilars and novel drugs. News

> SK Biopharmaceuticals, a drug developer spun out of South Korean conglomerate SK Holdings, is working with Chinese CROs PKU International HealthCare Group and Shanghai Medicilon to develop SKL-PSY, a treatment for depression and bipolar disorder. Item

> ACRO is asking the FDA for clarifications on draft guidance the group says paints a murky picture of how CROs should manage the transition to electronic trial data. More

Suggested Articles

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.

After three full business days in the position, an abrupt about-face has LabCorp Diagnostics’ CEO John Ratliff heading for the exit.

The initiative will see Evotec mine a kidney biobank for new renal therapy targets before the joint venture out-licenses resulting assets to Vifor.